Ab Initio Pharma

Ab Initio Pharma is revolutionizing the pharmaceutical landscape as a cutting-edge start-up and Contract Development and Manufacturing Organization (CDMO) in Australia. Specializing in GMP manufacturing of innovative respiratory, nasal, oral, and topical dosage forms for clinical trials, Ab Initio is at the forefront of pharmaceutical technology. Their state-of-the-art facilities and advanced processes ensure exceptional product quality and regulatory compliance, making them a trusted partner for pharmaceutical professionals and researchers alike.

Experiencing rapid growth and expansion, Ab Initio Pharma now operates across two sites in Sydney, covering both Research and Development (R&D) and GMP manufacturing. This strategic expansion underscores their commitment to supporting the entire drug development lifecycle, from early-stage research to full-scale clinical trial production. With a mission to build a sustainable and vibrant pharmaceutical ecosystem in Australia, Ab Initio Pharma empowers clinicians and pharmaceutical start-ups to bring life-changing treatments to market faster than ever before, shaping the future of healthcare.